Aude Bonehill

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6880067/publications.pdf

Version: 2024-02-01

41 papers	2,782 citations	201385 27 h-index	288905 40 g-index
41 all docs	41 docs citations	41 times ranked	2606 citing authors

#	Article	IF	Citations
1	Messenger RNA-Electroporated Dendritic Cells Presenting MAGE-A3 Simultaneously in HLA Class I and Class II Molecules. Journal of Immunology, 2004, 172, 6649-6657.	0.4	182
2	CD83 expression on dendritic cells and T cells: Correlation with effective immune responses. European Journal of Immunology, 2007, 37, 686-695.	1.6	173
3	Preclinical Evaluation of TriMix and Antigen mRNA-Based Antitumor Therapy. Cancer Research, 2012, 72, 1661-1671.	0.4	168
4	Enhancing the T-cell Stimulatory Capacity of Human Dendritic Cells by Co-electroporation With CD40L, CD70 and Constitutively Active TLR4 Encoding mRNA. Molecular Therapy, 2008, 16, 1170-1180.	3.7	166
5	A phase IB study on intravenous synthetic mRNA electroporated dendritic cell immunotherapy in pretreated advanced melanoma patients. Annals of Oncology, 2013, 24, 2686-2693.	0.6	158
6	Lentivirally transduced dendritic cells as a tool for cancer immunotherapy. Journal of Gene Medicine, 2003, 5, 654-667.	1.4	157
7	Current approaches in dendritic cell generation and future implications for cancer immunotherapy. Cancer Immunology, Immunotherapy, 2007, 56, 1513-1537.	2.0	149
8	Single-Step Antigen Loading and Activation of Dendritic Cells by mRNA Electroporation for the Purpose of Therapeutic Vaccination in Melanoma Patients. Clinical Cancer Research, 2009, 15, 3366-3375.	3.2	149
9	Therapeutic Vaccination With an Autologous mRNA Electroporated Dendritic Cell Vaccine in Patients With Advanced Melanoma. Journal of Immunotherapy, 2011, 34, 448-456.	1.2	124
10	mRNA-based dendritic cell vaccines. Expert Review of Vaccines, 2015, 14, 161-176.	2.0	121
11	Engineering Dendritic Cells to Enhance Cancer Immunotherapy. Molecular Therapy, 2011, 19, 841-853.	3.7	103
12	Induction of effective therapeutic antitumor immunity by direct in vivo administration of lentiviral vectors. Gene Therapy, 2006, 13, 630-640.	2.3	98
13	Electroporation of immature and mature dendritic cells: implications for dendritic cell-based vaccines. Gene Therapy, 2005, 12, 772-782.	2.3	85
14	Dendritic Cells Loaded With mRNA Encoding Full-length Tumor Antigens Prime CD4+ and CD8+ T Cells in Melanoma Patients. Molecular Therapy, 2012, 20, 1063-1074.	3.7	85
15	Side-by-Side Comparison of Lentivirally Transduced and mRNA-Electroporated Dendritic Cells: Implications for Cancer Immunotherapy Protocols. Molecular Therapy, 2004, 10, 768-779.	3.7	78
16	Optimized dendritic cell-based immunotherapy for melanoma: the TriMix-formula. Cancer Immunology, Immunotherapy, 2014, 63, 959-967.	2.0	74
17	Long-term clinical outcome of melanoma patients treated with messenger RNA-electroporated dendritic cell therapy following complete resection of metastases. Cancer Immunology, Immunotherapy, 2015, 64, 381-388.	2.0	70
18	Intravenous and intradermal TriMix-dendritic cell therapy results in a broad T-cell response and durable tumor response in a chemorefractory stage IV-M1c melanoma patient. Cancer Immunology, Immunotherapy, 2012, 61, 1033-1043.	2.0	63

#	Article	IF	Citations
19	Expression of human GITRL on myeloid dendritic cells enhances their immunostimulatory function but does not abrogate the suppressive effect of CD4+CD25+ regulatory T cells. Journal of Leukocyte Biology, 2007, 82, 93-105.	1.5	57
20	Genetic approaches for the induction of a CD4+ T cell response in cancer immunotherapy. Journal of Gene Medicine, 2005, 7, 686-695.	1.4	55
21	Modulation of Regulatory T Cell Function by Monocyte-Derived Dendritic Cells Matured through Electroporation with mRNA Encoding CD40 Ligand, Constitutively Active TLR4, and CD70. Journal of Immunology, 2013, 191, 1976-1983.	0.4	47
22	Induction of Influenza Matrix Protein 1 and MelanA-specific T lymphocytes in vitro using mRNA-electroporated dendritic cells. Cancer Gene Therapy, 2003, 10, 696-706.	2.2	46
23	Efficient presentation of known HLA class II-restricted MAGE-A3 epitopes by dendritic cells electroporated with messenger RNA encoding an invariant chain with genetic exchange of class II-associated invariant chain peptide. Cancer Research, 2003, 63, 5587-94.	0.4	45
24	Characterization of CD8⁺T-Cell Responses in the Peripheral Blood and Skin Injection Sites of Melanoma Patients Treated with mRNA Electroporated Autologous Dendritic Cells (TriMixDC-MEL). BioMed Research International, 2013, 2013, 1-8.	0.9	38
25	Design of an Optimized Wilmsâ€™ Tumor 1 (WT1) mRNA Construct for Enhanced WT1 Expression and Improved Immunogenicity In Vitro and In Vivo. Molecular Therapy - Nucleic Acids, 2013, 2, e134.	2.3	36
26	Activation of Monocytes via the CD14 Receptor Leads to the Enhanced Lentiviral Transduction of Immature Dendritic Cells. Human Gene Therapy, 2004, 15, 562-573.	1.4	31
27	Induction of antigen-specific CD8+ cytotoxic T cells by dendritic cells co-electroporated with a dsRNA analogue and tumor antigen mRNA. Gene Therapy, 2006, 13, 1027-1036.	2.3	30
28	Overcoming HLA restriction in clinical trials. OncoImmunology, 2012, 1, 1392-1394.	2.1	28
29	Dendritic cells differentiated in the presence of IFN-Î² and IL-3 are potent inducers of an antigen-specific CD8+T cell response. Journal of Leukocyte Biology, 2005, 78, 898-908.	1.5	27
30	Functional T-cell responses generated by dendritic cells expressing the early HIV-1 proteins Tat, Rev and Nef. Vaccine, 2008, 26, 3735-3741.	1.7	27
31	Epitope and HLA-type independent monitoring of antigen-specific T-cells after treatment with dendritic cells presenting full-length tumor antigens. Journal of Immunological Methods, 2012, 377, 23-36.	0.6	24
32	Immunotherapy of Cancer with Dendritic Cells Loaded with Tumor Antigens and Activated Through mRNA Electroporation. Methods in Molecular Biology, 2010, 629, 403-450.	0.4	24
33	Single-Step Antigen Loading and Maturation of Dendritic Cells Through mRNA Electroporation of a Tumor-Associated Antigen and a TriMix of Costimulatory Molecules. Methods in Molecular Biology, 2014, 1139, 3-15.	0.4	13
34	Delivery of Tumor-Antigen-Encoding mRNA into Dendritic Cells for Vaccination. Methods in Molecular Biology, 2008, 423, 155-163.	0.4	12
35	Lumenal Part of the DC-LAMP Protein Is Not Required for Induction of Antigen-Specific T Cell Responses by Means of Antigen-DC-LAMP Messenger RNA-Electroporated Dendritic Cells. Human Gene Therapy, 2010, 21, 479-485.	1.4	11
36	Restoration of tumor equilibrium after immunotherapy for advanced melanoma. Melanoma Research, 2011, 21, 152-159.	0.6	11

#	Article	IF	Citations
37	Inefficient exogenous loading of a tapasinâ€dependent peptide onto <scp>HLA</scp>â€<scp>B</scp>*44:02 can be improved by acid treatment or fixation of target cells. European Journal of Immunology, 2012, 42, 1417-1428.	1.6	7
38	Hemorrhagic regression of melanoma metastases during therapeutic vaccination: a report of three cases. Melanoma Research, 2009, 19, 385-390.	0.6	5
39	Enhancement of the antigen-specific cytotoxic T lymphocyte-inducing ability in the PMDC11 leukemic plasmacytoid dendritic cell line via lentiviral vector-mediated transduction of the caTLR4 gene. Molecular Medicine Reports, 2015, 12, 2443-2450.	1.1	4
40	Engineering WT1-Encoding mRNA to Increase Translational Efficiency in Dendritic Cells. Methods in Molecular Biology, 2016, 1428, 115-123.	0.4	1
41	Leukemic plasmacytoid dendritic cell line transduced with caTLR4 gene as a potent antigen presenting cells for immunotherapy. Cytotherapy, 2015, 17, S18.	0.3	0